New gene editing technique switches off cells ability to repair themselves

144 views
0

WHY THIS MATTERS IN BRIEF

  • When scientists edit DNA sometimes the cells natural repair mechanism undoes the modification, this new technique prevents that from happening and reduces the side effects of genetic modification


 

CRISPR, the revolutionary gene editing tool that’s also been dubbed the “Genesis Engine” because of its powerful applications, promises to radically change how diseases, from HIV and blindness to Cancer, are treated and is heralding in a new era in synthetic biology and artificial lifeforms – including designer humans and even complete artificial humans after 2036. Now, scientists at Western University in Ontario have edited the editor, adding a new engineered enzyme to CRISPR that can help prevent the target DNA from repairing itself and canceling out the new genetic changes.

With human trials of gene editing happening in a number of fields CRISPR’s power comes from the ability to let scientists swap out sections of DNA, removing unwanted genes like those that might cause cancer or other diseases, and splicing in more helpful ones, but unfortunately cells have a natural ability to fight back against the “damage” to their DNA strands and in some cases they can use an in house repair system, using what’s known as a “Genetic template” to undo the effects.

 

RELATED
Solar powered artificial skin gives prosthetics a sense of touch

 

“The problem with CRISPR is that it will cut DNA, but then DNA-repair will take that cut and stick it back together,” says David Edgell, principal investigator of the study, “that means it is regenerating the site that the CRISPR is trying to target, creating a futile cycle. The novelty of our addition is that it stops that regeneration from happening.”

The addition in question is an enzyme called I-Tevl, which is combined with Cas9, the DNA cutting enzyme that gives the CRISPR-Cas9 tool its name, but where Cas9 only makes cuts in one site on the genome, the newly created “TevCas9” cuts in two places, making it much harder for the cell to repair itself.

 

 

As an added bonus, using TevCas9 appears to reduce the chances of unwanted side effects as a result of the cutting by targeting genes much more directly. This is another benefit of the new technique because sometimes when the genetic makeup of a cell is edited there are “unintended consequences” and this new technique could help stop – or at least limit those from happening.

“Because there are two cut-sites, there is less chance that these two sites occur randomly in the genome; much less chance than with just one site,” says co-author, Caroline Schild-Poulter.

“This remains to be tested, but this is the hope and the expectation.”

About author

Matthew Griffin

Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the 311 Institute, a global futures and deep futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future.” Regularly featured in the global media, including AP, BBC, CNBC, Discovery, RT, and Viacom, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Bain & Co, BCG, BOA, Blackrock, Bentley, Credit Suisse, Dell EMC, Dentons, Deloitte, Du Pont, E&Y, GEMS, HPE, Huawei, JPMorgan Chase, KPMG, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, UBS, and many more.

Your email address will not be published. Required fields are marked *